An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis
SKIN The Journal of Cutaneous Medicine（2020）
摘要
Abstract not available.
更多查看译文
关键词
reduced absolute psoriasis area,selective tyrosine kinase,deucravacitinib,inhibitor
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要